Patients with infl ammatory bowel disease (IBD) frequently receive immunosuppressive therapy. The immune response in these patients to vaccines has not been well studied. We conducted a prospective, open label study to evaluate the serologic response to infl uenza vaccine in children with IBD. 
INTRODUCTION
Patients with Crohn ' s disease (CD) and ulcerative colitis (UC) are presumed to have chronic intestinal in ammation as a result of an altered immune response to an environmental or infectious trigger (1) . A number of genetic mutations associated with CD and / or UC suggest that a ected patients have subtle defects in innate immunity (2 -5) . In ammatory bowel disease (IBD) patients are o en placed on long-term antiin ammatory and immunosuppressive therapies, including aminosalicylates, corticosteroids, 6-mercaptopurine, azathioprine, methotrexate, and in iximab (6) . Although a majority of IBD patients do not develop serious infections, reports of life-threatening infections (e.g., varicella, tuberculosis) have been published, primarily in patients receiving immunosuppressive therapy (7 -10) .
In 2004, a consensus report of a committee organized by the Crohn ' s and Colitis Foundation of America recommended the administration of routine inactivated vaccines to IBD patients (11) . However, there is a paucity of formal vaccine studies that examine the serologic response to routine immunizations in this population. One earlier study by Mamula et al . (12) suggested that children with IBD may mount an inadequate immune response to one strain of the inactivated in uenza vaccine compared to healthy controls.
In uenza is a contagious acute respiratory infection that may cause serious complications (13) . In the United States, in uenza was responsible for more than 226,000 hospitalizations annually from 1979 to 2001 and 36,000 deaths annually from 1990 to 1999 (14, 15) . People with certain medical conditions (e.g., chronic lung disease, malignancy) may be at a higher risk of having complications if they are infected with in uenza (16, 17) . Other groups of patients (e.g., those with pulmonary or cardiac disease) may have exacerbations of their underlying illness (13) . In one study of children younger than 16 years old, the in uenza vaccine had an e cacy rate between 77 % (in uenza A / H3N2) and 91 % (A / H1N1) in protecting against culture-proven in uenza infections (18) . e vaccine may be less e ective in people with certain medical conditions (e.g., systemic lupus erythematosus) (19, 20) or in patients receiving immunosuppressive medications (12, 21) .
e serologic response to vaccines (including in uenza vaccine) in children with IBD is not well studied. To further evaluate this question, we conducted a prospective, open label study to evaluate the safety and immunogenicity of inactivated in uenza vaccine in a cohort of pediatric IBD patients. We hypothesized that children receiving immunosuppressive therapy would be less likely to develop a serologic response to the vaccine.
METHODS

Patients
We recruited patients ages 5 years or older from the IBD outpatient program or during hospital admissions at Children ' s Hospital Boston who had documented CD, UC, or indeterminate colitis (IC). e lower age limit was set at 5 years to capture the vast majority of the pediatric IBD population.
e diagnosis of CD, UC, and IC (22,23) was established by standard clinical, radiographic, endoscopic, and histologic criteria. Exclusion criteria included: (i) contraindication to receiving in uenza vaccine (e.g., allergic reaction to prior in uenza vaccine, egg allergy), (ii) previous in uenza vaccination during the current in uenza season, (iii) fever within 48 h before in uenza vaccination, and (iv) receipt of another vaccine within 48 h before in uenza vaccination. We asked that patients should not receive another immunization within 48 h a er in uenza vaccination to minimize confounding of acute adverse event reporting.
Groups
Patients were categorized into two main groups depending on whether their IBD treatments were thought to cause immunosuppression: (i) nonimmunosuppressed (NIS) or (ii) immunosuppressed (IS). Patients were classi ed as NIS if they received no therapy, antibiotics only, or aminosalicylates only at the time of vaccination ( Table 1 ) . Patients were classi ed as IS if they received tacrolimus, in iximab, adalimumab, thalidomide, 6-mercaptopurine, azathioprine, methotrexate, or corticosteroids at the time of vaccination. Standard concomitant medications (e.g., antibiotics, antihistamines, acetaminophen) were allowed.
A priori , we assumed there were varying degrees of immune response to in uenza vaccination depending on the type of immunosuppressive therapy patients received.
erefore, patients within the IS group were further subcategorized by the speci c medications they received at the time of vaccination: (i) tacrolimus, (ii) tumor necrosis factor-(TNF-) inhibitor (in iximab, adalimumab, thalidomide), (iii) immunomodulator (6-mercaptopurine, azathioprine, methotrexate), and (iv) corticosteroids only (prednisone, prednisolone, methylprednisolone) ( Table 1 ) . Patients receiving both an immunosuppressive medication and prednisone were categorized by the immunosuppressive therapy (e.g., a patient receiving both 6-mercaptopurine and prednisone was placed in the 6-mercaptopurine group). Patients who received at least two immunosuppressive therapies were classi ed by the medication that had the greatest immunosuppressive e ect. Tacrolimus and TNF- inhibitors were thought to have the most immunosuppressive potency, and immunomodulators the least immunosuppressive potency of these three classes of medications. For example, a patient on in iximab and 6-mercaptopurine was placed in the TNF-inhibitor group. None of our patients received both tacrolimus and TNF-inhibitor.
Study design
Patients were recruited between October 2007 and December 2007. Each patient had two study visits (entry and a er vaccination), as outlined in Figure 1 .
Entry visit . Written informed consent was obtained from the parent / guardian of patients < 18 years old, and from patients if they were ≥ 18 years old. Each patient answered a questionnaire focused on demographics, medical history related to IBD, medications, and possible in uenza-like symptoms. On the basis of the clinical information obtained, the Montreal classi cation (24) (a widely used disease phenotyping system in IBD research) was used to de ne disease location and behavior. In each patient, a physical examination was performed and clinical IBD laboratory studies were obtained including: complete blood count, erythrocyte sedimentation rate, and albumin. Disease activity was assessed by the Pediatric Crohn ' s Disease Activity Index (25) for patients with CD, and the Modied Harvey -Bradshaw score (26) for patients with UC or IC. Serum was obtained for determination of baseline in uenza titer (pre-vaccination), immediately followed by immunization with a 0. Pasteur, Swi water, PA). In accordance with recommendations of the Advisory Committee on Immunization Practices from the Centers for Disease Control and Prevention, children ≤ 8 years old received two doses ≥ 4 weeks apart if they were receiving the in uenza vaccine for the rst time, or if they had received only one dose of in uenza vaccine during the previous in uenza season as their rst dose (13) .
A standard 0.5 ml dose of vaccine contained 15 g hemagglutinin of each in uenza strain, residual egg protein, and gelatin.
ere were no antibiotics or thimerosal in the manufacture of the vaccines used (27) . Participants were instructed to contact the study sta immediately if they experienced adverse events (e.g., life-threatening event or hospitalization related to the vaccine) a er immunization. If patients did not contact the study sta , they were called approximately 48 h a er vaccination to inquire about side e ects and adverse events. 
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Response to Influenza Vaccine in Children With IBD cyte sedimentation rate, and albumin). Severity of disease was reassessed using the Pediatric Crohn ' s Disease Activity Index or Modi ed Harvey -Bradshaw score.
e study was approved by the institutional review board at Children ' s Hospital Boston. An independent Data Safety Monitor Board monitored the study for adverse events.
Specimen handling and laboratory analysis
Sera to be used for measurement of in uenza titers were stored at − 80 ° C. Samples were sent on dry ice in a batch to the Laboratory for Specialized Clinical Studies at Cincinnati Children ' s Hospital Medical Center (Cincinnati, OH) for analysis. e laboratory was blinded to subject identi ers, diagnosis, and medication group. Sera were assessed for antibody to each of the three components of the vaccine by hemagglutination inhibition (HAI) assay using standard methods (28) . In brief, sera were treated with receptor-destroying enzyme (DenkaSeiken, Japan) to remove nonspeci c inhibitors of hemagglutination before testing. Following receptor-destroying enzyme treatment, the samples were further diluted to 1:10 in phosphate-bu ered saline. e sera were then treated with packed red blood cells to remove nonspeci c inhibitors. e red blood cells were spun out of the sera and the samples were ready for testing. Starting at 1:10 dilution, the sera were diluted twofold through 1:2,560 in V-bottom microtiter plates.
Egg-derived, inactivated viral antigens (A / H1N1, A / H3N2, and B / Malaysia) representative of the 2007 -2008 vaccine were obtained from the Centers for Disease Control and Prevention, added to serially diluted sera, and incubated at room temperature for 30 min. Red blood cells from turkey blood (Viromed Laboratories, Minnetonka, MN) were suspended at a concentration of 0.5 % in phosphate-bu ered saline, added to the serum -viral antigen mixture, and incubated at room temperature for 30 min. Plates were tilted and read. e antibody titers were reported as the reciprocal of the last serum dilution to completely inhibit red blood cell agglutination. Sera without reactivity were assigned a value of < 10. Sera with initial titers of ≥ 2,560 were retested at a higher starting dilution to obtain a reportable titer.
Study outcomes e primary outcome was seroprotection, de ned as an HAI titer ≥ 40 (27) to each in uenza strain. e secondary outcome was the antibody titer to each in uenza strain. e tertiary outcome was the number and type of acute vaccine-associated side e ects and adverse events.
Statistical analysis
Characteristics of patients groups . Demographic characteristics, medical history, medications, disease activity, laboratory data, and Montreal classi cation were described for NIS and IS groups. For continuous variables, di erences between groups were compared using t -tests. If there was evidence for nonnormality, nonparametric statistics were used. For dichotomous variables, di erences between groups were compared using 2 -or Fisher ' s exact test.
Seroprotection . At each time point (pre-and post-vaccination), we calculated the proportion of patients in the NIS and IS groups with a seroprotective titer (HAI ≥ 40) to each in uenza strain (proportion seroprotected). We examined the di erence in proportions between the two groups using a Fisher ' s exact test. We performed the above analysis in three ways: (i) among patients who completed the study regardless of their titer at entry, (ii) among patients who were not seroprotected at entry (HAI < 40), and (iii) among patients who were seronegative at entry (HAI < 10).
Geometric mean titer . We compared the post-vaccination geometric mean titers (GMTs) between the NIS and IS groups using two-sample t -tests for each in uenza strain. If there was evidence for non-normality, the Wilcoxon test was used.
Medication subgroup analyses . We strati ed the IS group by medication class (tacrolimus, TNF-inhibitor, immunomodulator, and corticosteroids only). We used logistic regression analysis to compare the proportion seroprotected in each of the four subgroups to the NIS group. For example, four dummy variables were created, with NIS as the reference group. We used analysis of variance to compare di erences in post-vaccination titers across the medication and NIS groups. We used Tukey ' s honestly signi cant di erences test to adjust for multiple comparisons.
Acute side e ects and adverse events . We evaluated the difference in frequency of types of acute side e ects and adverse events between the two IBD groups using a 2 -or Fisher ' s exact test. In addition, we compared pre-and post-vaccination disease activity scores using the sign test. All statistical tests were performed using SPSS 15.0 for Windows (29) .
Power calculations
Before conducting the study, we calculated the di erences in proportion seroprotected between the NIS and IS groups. We used the proportions seroprotected in a prior in uenza immunization study of healthy children by Chiu et al . (30) to estimate the proportion seroprotected in the NIS group. We assumed an of 0.05 with continuity correction and 80 % power. Given 65 patients per group (IS, NIS), we determined that we would be able to detect a di erence of 16 % for H1N1, 14 % for H3N2, and 20 % for B strain between the NIS and IS groups. We enrolled additional patients in the IS group, so that we could conduct subanalyses based on the class of immunosuppressive agent. All power calculations were performed using the program PASS (31) .
RESULTS
Study demographics
We enrolled 146 patients (96 CD, 47 UC, and 3 IC) into the study: 20 were receiving no therapy, antibiotics only, or aminosalicylates only (NIS group), and 126 were receiving studies ( N = 76), the proportion seroprotected against the A / H1N1 and A / H3N2 were similar between the historical healthy controls and the NIS or IS group in our study. e data in healthy controls suggested that strain B was less immunogenic overall; the proportion seroprotected was 57 % for controls, compared to 42 % for our NIS group and 39 % for our IS group (32) .
The proportion seroprotected at post-vaccination is similar between NIS and IS groups among patients who did not have seroprotective levels (HAI < 40) at entry
We conducted a subanalysis to determine the proportion seroprotected at post-vaccination among patients who did not have a seroprotective titer (HAI < 40) at entry ( Table 4 ) . Overall, we did not nd a di erence in the proportion seroprotected between the NIS and IS groups for any of the three in uenza strains.
However, in an analysis of IS subgroups, patients receiving TNF-inhibitors had a signi cantly lower proportion seroprotected against strain B (14 % ) compared to patients in the NIS group (39 % , P = 0.025). ere were no signi cant differences in the proportion seroprotected between each of the other subclass medication groups compared to the NIS group for any vaccine strain. In addition, there was no di erence in the proportion seroprotected between patients on both TNF-inhibitor and an immunomodulator compared to patients on TNF-inhibitor without an immunomodulator (data not shown).
The proportion seroprotected at post-vaccination is similar between NIS and IS groups among patients who were seronegative (HAI < 10) at entry
We conducted another subanalysis of the proportion seroprotected at post-vaccination among patients who were seronegative (HAI < 10) at entry ( Table 5 ). Overall, we did not identify a di erence in the proportion seroprotected between the NIS and IS groups for any of the three in uenza strains. ere were immunosuppressive therapy (IS group).
e number of patients who completed the study was 137 ( Figure 2 ). e baseline characteristics for enrolled patients are shown in Table 2 . e median disease activity scores for both CD and UC groups were compatible with disease in remission.
The proportion seroprotected at post-vaccination is similar between nonimmunosuppressed and immunosuppressed IBD patients
e proportion seroprotected against each in uenza vaccine strain pre-and post-vaccination are shown by medication group in Table 3 .
e proportion seroprotected at postvaccination for each in uenza A strain (A / H1N1 and A / H3N2) was compared to the B strain for each IBD group. ere was a statistically signi cant higher proportion seroprotected in both A strains than the B strain, irrespective of whether patients were receiving immunosuppressive therapy ( P < 0.02 for all comparisons).
Overall, the proportion seroprotected at post-vaccination was similar between the NIS and IS groups for all three in uenza strains.
We also compared the proportion seroprotected in each subclass within the IS group (tacrolimus, TNF-inhibitor, immunomodulator, and corticosteroids only) to the NIS group. We found no signi cant di erences in the proportion seroprotected between any medication subgroup and the NIS group. Of patients receiving TNF-inhibitors, a lower percentage (21 % ) responded to the B strain. However, the di erence was not statistically signi cant.
In Table 3 , we compared the proportion of patients who were seroprotected at post-vaccination in our study to a cohort of pediatric historical healthy controls who were immunized with the same in uenza strains during the same in uenza season (2007 -2008) as the IBD patients in our study. Data for these historical controls were obtained from studies reported to the Vaccines and Related Biological Products Advisory Committee from the Food and Drug Administration (32) . In these 
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The post-vaccination geometric mean titer is similar between NIS and IS IBD patients
GMTs are a quantitative measure of antibody response to immunization.
e pre-and post-vaccination GMTs for each group in our study population and for the pediatric historical healthy controls are presented in Table 6 . Overall, there was no di erence in post-vaccination GMTs between the NIS and IS groups for any of the three in uenza strains.
e GMTs for each subclass of immunosuppressive medication were compared with those for the NIS group. e " corticosteroids-only " group had a signi cantly higher postvaccination GMT for strain B (80) compared to the NIS group (22, P = 0.005) and other immunosuppressive medication groups ( P ≤ 0.003) except tacrolimus ( P = 0.33). ere were no di erences between the corticosteroids-only group and the NIS group for post-immunization GMTs to the two A strains.
ere was no di erence in any of the other post-vaccination GMTs for the IS subclasses compared to the NIS group.
Adverse events
ere were no serious adverse events related to the in uenza vaccine during the study. Reported side e ects from vaccination are listed in Table 7 . e most common side e ect was soreness at the injection site (38 % , n = 146). Local reactions to vaccination, upper respiratory symptoms, headache, and systemic symptoms occurred in ≤ 5 % of all patients. ere was no di erence in side e ects from vaccination between the NIS and IS groups.
During the period of patient follow-up for this study (i.e., between the patient ' s rst and second study visits), six patients were hospitalized for IBD-related issues: four for electively scheduled colectomies, and two for ares of IBD. None of also no di erences in the proportion seroprotected between each medication within the IS group compared to the NIS group for any vaccine strain. Pediatric historical healthy controls were immunized with the same infl uenza strains during the same infl uenza season (2007 -2008) as IBD patients in our study. Data for these historical controls were obtained from studies reported to the Vaccines and Related Biological Products Advisory Committee from the Food and Drug Administration (32) . At post-vaccination, the proportion seroprotected was similar between the NIS and IS groups for all three infl uenza strains ( P >0.46 for all strains): A/H1N1 (NIS 100%, IS 95%), A/H3N2 (NIS 84%, IS 89%), and B (NIS 42%, IS 39%). TNF-, tumor necrosis factor-; HAI, hemagglutination inhibition. At post-vaccination, the proportion seroprotected was similar between the NIS and IS groups for all three infl uenza strains ( P >0.34 for all strains): A/H1N1 (NIS 100%, IS 86%), A/H3N2 (NIS 50%, IS 74%), and B (NIS 39%, IS 30%). a In an analysis of IS subgroups, only patients receiving TNF-inhibitors had a signifi cantly lower proportion seroprotected against strain B (14%) compared to patients in the NIS group (39%, P =0.025). 
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Response to Influenza Vaccine in Children With IBD these hospitalizations were thought to be related to in uenza immunization. In addition, there was no statistically signi cant di erence between pre-and post-vaccination disease activity scores ( P = 0.69 for the Pediatric Crohn ' s Disease Activity Index, P = 0.85 for Modi ed Harvey -Bradshaw score).
DISCUSSION
Our prospective study of IBD patients who received in uenza vaccine indicates that the vaccine is both safe and immunogenic in this population. e in uenza vaccine was well tolerated with a low percentage of side e ects and without serious adverse events related to the vaccine. Severity of disease activity was not a ected by immunization. A high proportion of patients with CD and UC immunized with the standard in uenza vaccine were seroprotected irrespective of whether they were receiving immunosuppressive therapy. However, on subanalysis of patients who were not seroprotected before immunization, a lower proportion of patients receiving TNF-inhibitors were seroprotected against in uenza strain B / Malaysia than other patient groups.
is has important implications because these patients are at risk for acquiring in uenza strain B and its complications. Concomitant use of an immunomodulator with TNF-inhibitor did not a ect the proportion seroprotected and post-vaccination GMT for any strains (data not shown).
We were surprised to learn that patients on tacrolimus did not have a lower proportion seroprotected, as both TNF-inhibitors and tacrolimus are immunosuppressive therapies that a ect T cells. Even though corticosteroids may also a ect T cells, the patients in the " corticosteroidsonly " group were receiving only a relatively low dose of the medication.
Vaccine trials conducted in patients with chronic illness have demonstrated varying degrees of seroprotection. Adults with systemic lupus erythematosus have a lower antibody response to pneumococcus (33, 34) , tetanus (35) , and in uenza (19, 20) compared to controls. In contrast, response to the in uenza vaccine appears adequate in adults with asthma receiving corticosteroids (36) and in rheumatoid arthritis (37) . A study of pediatric oncology patients who received two doses of in uenza vaccine demonstrated a 40 -65 % seroconversion rate and 38 -72 % seroprotection rate to the three in uenza strains in unprimed patients. However, patients receiving chemotherapy had a lower immune response to in uenza A strains compared to patients who completed chemotherapy 1 -6 months before the study. is latter group of children who no longer received chemotherapy exhibited a similar immune response to healthy children (21) .
Only one other study has prospectively evaluated vaccine serologic responses in children with IBD. 
